Search, analyze & compare

My selected companies

Adjust valuation method
WatchlistNameTickerP/EP/SP/BEV/EbitdaROEROICRSISMA200DCFVolumeClosing price
-
Arcellx, Inc.ACLX-109.6730.638.93-64.94-10.79%-7.73%37.22$87.56$407.781,893$82.84

Detail of Arcellx, Inc.

 
CEO
Mr. Rami Elghandour
Employees
78
Industry
Biotechnology
Sector
Healthcare
Market cap
$4B

Company details

Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.

Revenue
Revenue (Rev)
$144.74M
Arcellx, Inc.
ACLX • XNGS • US
$82.84
+30.48 (58.21%)
Stock vs Industry average
  • Industry average

Negative values are hidden from the graph.
Trailing annual dividend rate
$0.00
Payout ratio
0.00%
EPS
-$0.76
Margin profit
-25.94%
52 week low
$49.740002
52 week high
$106.529999
50-day simple moving average
$88.84
200-day simple moving average
$87.56
Percent held by insiders
12.62%
Percent held by institutions
93.10%
Dividend yield
0.00%

Change of shares

Cash vs Debt

Insider Trading

Comparison of selected companies

 
%
Price change
ACLX +58.21%
eps change
ACLX 0.00%